Strategic Execution and Operational Pivot – Performance was driven by consistent demand for ORLADEYO capsules and a 45% year-over-year increase in total revenue, excluding divested European operations. – Management completed a strategic pivot by discontinuing internal drug…
scovery and closing the Birmingham research unit to reallocate resources toward external asset acquisition. – The pediatric launch of ORLADEYO pellets is exceeding expectations with 47 prescriptions received before official shipping began, representing nearly 10% of the known diagnosed pediatric market. – Operational efficiency improved through the transition to CareMed as a sole-source pharmacy partner, selected for its ability to scale alongside the growing HAE portfolio. – Market dynamics show that new injectable competitors are primarily impacting existing injectable therapies like TAKHZYRO, while ORLADEYO’s patient retention remains stable. – The paid therapy rate reached 84%, a slight improvement over the previous year, reflecting successful navigation of the heavy reauthorization season. Outlook and Strategic Priorities – Full-year 2026 ORLADEYO revenue guidance is maintained at $625 million to $645 million, assuming long-term growth trends remain intact despite the pediatric manufacturing delay. – Top-line data for the navenibart ALPHA-ORBIT pivotal study is expected in the third quarter of 2027, with the study remaining blinded to collect a full year of safety and efficacy data. – The company expects to report proof-of-concept data for BCX17725 in Netherton syndrome by the end of 2026, with enrollment currently on track. – Management is targeting a leaner operating model with non-GAAP operating costs guided to $420 million to $440 million, benefiting from the closure of legacy R&D facilities. – Future business development will prioritize high-quality, mid-stage clinical assets with validated biology, funded through existing cash flow rather than large capital raises
Structural Changes…